Welcome to our dedicated page for Orthopedia SEC filings (Ticker: KIDS), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Medical device filings can be dense; OrthoPediatrics’ reports add an extra layer of complexity with clinical trial data, FDA submissions, and unique pediatric implant metrics spread across hundreds of pages. Investors often ask, “Where is the limb deformity revenue?” or “Did executives buy shares ahead of a 510(k) clearance?” Stock Titan answers by delivering OrthoPediatrics SEC filings explained simply through concise AI-powered summaries as soon as each document lands on EDGAR.
Need the numbers fast? Our platform links every OrthoPediatrics quarterly earnings report 10-Q filing to instant trend charts, while the latest OrthoPediatrics annual report 10-K simplified highlights segment sales, R&D spending, and regulatory milestones. Receive alerts on OrthoPediatrics insider trading Form 4 transactions and drill further with OrthoPediatrics Form 4 insider transactions real-time to spot buying or selling by surgeons turned directors. Material announcements are decoded in seconds with OrthoPediatrics 8-K material events explained, and each OrthoPediatrics proxy statement executive compensation call-out lets you see how leadership pay aligns with growth.
Behind the scenes, our AI dissects language, numbers, and footnotes, turning dense paragraphs into clear takeaways, so understanding OrthoPediatrics SEC documents with AI becomes part of your daily workflow. Practical uses abound:
- Compare revenue trends using our OrthoPediatrics earnings report filing analysis
- Flag sudden share movements via OrthoPediatrics executive stock transactions Form 4
- Track device approvals and recalls without sifting through PDFs
With comprehensive coverage, real-time updates, and expert commentary, Stock Titan turns complicated disclosures into actionable insights—so you can focus on evaluating growth in pediatric orthopedics, not downloading filings.
OrthoPediatrics Corp. reported Q3 2025 results. Net revenue rose to $61,250 thousand from $54,573 thousand, with gross profit of $45,274 thousand. Operating expenses included intangible asset impairment of $2,268 thousand and restructuring of $2,294 thousand, resulting in an operating loss of $9,428 thousand versus $5,566 thousand a year ago. Net loss was $11,773 thousand, or $0.50 per share.
For the nine months, revenue reached $174,743 thousand versus $152,060 thousand, while net loss was $29,545 thousand. Cash was $16,826 thousand and short‑term investments were $40,902 thousand as of September 30, 2025. The company had a term loan of $51,000 thousand and a $50,000 thousand convertible note outstanding. It drew $25,000 thousand from its delayed‑draw term loan on June 27, 2025. Net cash used in operating activities was $15,199 thousand year‑to‑date.
U.S. sales were $48,718 thousand and international sales were $12,532 thousand in Q3. Shares outstanding were 25,077,330 as of October 28, 2025.
OrthoPediatrics Corp. (KIDS) furnished an investor presentation. The company’s executive officers plan upcoming presentations to investors and analysts and intend to use materials included as Exhibit 99.1, titled “OrthoPediatrics Corp. Investor Presentation” dated October 2025.
The materials are provided under Item 7.01 (Regulation FD) and are furnished, not filed, meaning they are not subject to liability under Section 18 of the Exchange Act and are not incorporated into other Securities Act or Exchange Act filings unless specifically referenced.
OrthoPediatrics Corp. furnished an 8-K announcing its earnings for the quarter ended September 30, 2025. The press release, including unaudited condensed consolidated financial statements and other financial data, is attached as Exhibit 99.1 and incorporated by reference.
The information under Item 2.02 is furnished and not deemed “filed” under Section 18 of the Exchange Act or incorporated by reference except as expressly set forth.
Orthopedics Corp (KIDS) disclosed that it has prepared preliminary net revenue estimates but these figures are subject to completion of the company's audit and may change. The company warns that results for the third quarter and for the full year could differ materially from the preliminary estimates and cautions readers not to place undue reliance on forward-looking statements. Investors are directed to the Risk Factors discussion in the company's Annual Report filed with the SEC for factors that could cause actual results to diverge. The company also states it will not update these forward-looking estimates publicly unless required by law.
OrthoPediatrics Corp. (KIDS) Form 4: Chief Operating Officer and Chief Financial Officer Fred Hite purchased 5,076 shares of OrthoPediatrics common stock in the open market on 08/21/2025 at $19.41 per share, bringing his beneficial ownership to 213,065 shares including 150,360 restricted shares. The filing notes the purchase was matchable under Section 16(b) with a prior sale, and Mr. Hite disgorged $27,664.20 to the company representing the full short-swing profit.
The transaction was reported by an attorney-in-fact on 08/25/2025. The Form 4 shows direct ownership and does not report derivative transactions. No additional executive departures, changes in compensation, or forward-looking statements are included in the filing.
OrthoPediatrics announced the Board accepted the resignation of director Terry Schlotterback due to retirement, effective August 8, 2025; the filing states the departure was not due to any disagreement with the Company. The Board appointed Kelly Fischer to fill the vacancy and to serve in the director class expiring at the annual stockholder meeting in 2026. Ms. Fischer has been Senior Vice President and Chief Financial Officer of Cook Medical since 2003 and will join the Board's Audit Committee and Compensation Committee.
For her service, Ms. Fischer will be eligible to receive a pro rata portion of the 2025 Award under the Company's Non-Employee Director Compensation Policy (described in Exhibit 10.1 to a recent Quarterly Report). The Board also agreed that the remaining 10,900 unvested restricted shares previously granted to Mr. Schlotterback will remain outstanding and continue to vest on their scheduled timelines as though he remained a director. The company disclosed no material plans, contracts or related-party transactions involving Ms. Fischer.
FAQ
What is the current stock price of Orthopedia (KIDS)?
What is the market cap of Orthopedia (KIDS)?
